Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 8/20 | 0.57 |
| ▸ | TP53 | P04637 | 5/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16480591 | 0.86 | PLA2G10 (0.48) | THRBLMNATP53RXFP1MEN1 | |
| SCHEMBL30547707 | 0.84 | KDM4E (0.68) | THRBLMNATP53RXFP1MEN1 | |
| SCHEMBL5599830 | 0.84 | KDM4E (0.68) | THRBLMNATP53RXFP1MEN1 | |
| SCHEMBL6086802 | 0.83 | CLK1 (0.61) | THRBLMNATP53RXFP1L3MBTL1 | |
| SCHEMBL28238032 | 0.83 | KDM4E (0.60) | THRBRXFP1KMT2AL3MBTL1MAPT | |
| SCHEMBL4744999 | 0.81 | KDM4E (0.73) | THRBLMNATP53RXFP1MEN1 | |
| SCHEMBL13415456 | 0.81 | RXFP1 (0.62) | RXFP1MEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL12868305 | 0.80 | THRB (0.58) | THRBLMNATP53RXFP1MEN1 | |
| SCHEMBL7877590 | 0.80 | L3MBTL1 (0.72) | THRBLMNATP53RXFP1MEN1 | |
| SCHEMBL9613272 | 0.79 | TP53 (0.47) | LMNATP53RXFP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423435-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-1727797-B1 | PROCESS FOR CROSS COUPLING INDOLES | BOEHRINGER INGELHEIM PHARMA (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2335700-A1 | Hepatitis C virus polymerase inhibitors with a heterobicylic structure | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2011-06-22 | — | — | EP | disclosed |
| US-7893084-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-20090087409-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-04-02 | — | — | US | disclosed |
| EP-1891951-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087409-A1 | Viral Polymerase Inhibitors | NR2C2, NR4A1, MED25 | THRB 1251/4885LMNA 2665/4885TP53 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.